Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651795 | 0.87 | MEP1B (0.38) | TAS2R14MEP1BHSD17B2LIMK2MTNR1B | |
| SCHEMBL4126794 | 0.86 | CA12 (0.39) | L3MBTL1 | |
| SCHEMBL3651797 | 0.85 | TAS2R14 (0.39) | TAS2R14MEP1BHSD17B2PGRMTNR1B | |
| SCHEMBL4129164 | 0.85 | HTR6 (0.38) | TAS2R14LIMK2 | |
| SCHEMBL3655896 | 0.82 | KAT6A (0.42) | TAS2R14MEP1BHSD17B2PGRLIMK2 | |
| SCHEMBL4131739 | 0.80 | MEP1B (0.42) | MEP1BMTNR1BCLK1HSD11B1AKR1B1 | |
| SCHEMBL3652101 | 0.78 | KAT6A (0.36) | TAS2R14MEP1BHSD17B2LIMK2MTNR1B | |
| SCHEMBL3652103 | 0.77 | KAT6A (0.36) | TAS2R14MEP1BHSD17B2PGRLIMK2 | |
| SCHEMBL3654644 | 0.75 | HTR2C (0.38) | — | |
| SCHEMBL2837806 | 0.75 | EDNRA (0.44) | HSD17B2MTNR1BCLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | TAS2R14 329/4885MEP1B 940/4885HSD17B2 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.